The Canadian National Stock Exchange has not approved nor disapproved
the contents of this press release.
VANCOUVER, May 26, 2011 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce that Health Canada has
approved its advanced wound care product Collacare® (the "Product") for
sales and distribution in Canada. The Product is exclusively licensed
to Merus Labs by Innocoll. Collacare® is indicated for the management
of ulcers, burns, split-skin donor sites and other dermal wounds.
The product is a biodegradable, implantable advanced wound care device
made up of bioactive collagen dressing. Collagen is a
well-characterized structural protein that occurs naturally in animals.
Collacare® forms a gel-like sheet that assumes the shape of the wound
bed so as to maintain a moist environment to aid the wound healing
With the approval of Collacare®, Merus currently has 7 wound care
products that will be launched in the next 3 to 4 months. The 6 other
wound care products consist of Foam Dressings, Isolate Hydrophilic
Dressings, Excel Hydrocolloid transparent wound dressings, Tulip Sacral
Ulcer Wound Dressing as well as, Repel & Spot wound dressings. These
products are indicated for pressure ulcers, trauma wounds, donor sites,
diabetic ulcers, arterial venous ulcers as well as 1st and 2nd degree
burns. In addition to the above products the Company has several other
wound care products under development that are designated for launch in
the next 2 or 3 quarters.
"We are very pleased with the Approval of Collacare® by Health Canada.
Collacare® will provide Canadian patients and health care providers
with an advanced biodegradable and implantable device that will greatly
accelerate wound healing. We look forward to the launch of our line of
wound care products in the next quarter." said Ahmad Doroudian,
President and CEO.
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products
in Canada andUnited States. Merus further enhances the sale and
distribution of these products by introduction of a focused marketing
and promotion plan.
About Innocoll Inc.
Innocoll is an international biopharmaceutical company focused on
targeted delivery products primarily in the areas of biodegradable
surgical implants and topically applied healthcare products. The
company has developed and manufactures a range of pharmaceutical
products and medical devices using their proprietary collagen-based
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783